Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00535080 | Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease | no longer available | — | — | Galderma R&DINDUSTRY | 0 | Feb 18, 2021 | clinicaltrials |
| NCT02354612 | Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial | no longer available | — | — | Tracon Pharmaceuticals Inc.INDUSTRY | 1 |
| Feb 15, 2021 |
| clinicaltrials |
| NCT02475382 | Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen(CheckMate 169) | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 2 | Nov 27, 2020 | clinicaltrials |
| NCT04644107 | Expanded Access for Marizomib | no longer available | — | — | CelgeneINDUSTRY | 1 | Nov 25, 2020 | clinicaltrials |
| NCT01151930 | Long-Term Compassionate Use Study for Continued Administration of SCB01A-01 | no longer available | — | — | SynCore Biotechnology Co., Ltd.INDUSTRY | 0 | Nov 17, 2020 | clinicaltrials |
| NCT01947608 | Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 10 | Nov 3, 2020 | clinicaltrials |
| NCT01196208 | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 | no longer available | — | — | Seagen Inc.INDUSTRY | 15 | Sep 21, 2020 | clinicaltrials |
| NCT02889445 | A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers | no longer available | — | — | DEKK-TEC, Inc.INDUSTRY | 1 | Aug 18, 2020 | clinicaltrials |
| NCT04137822 | Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer | no longer available | — | — | Impatients N.V. trading as myTomorrowsINDUSTRY | 2 | Aug 14, 2020 | clinicaltrials |
| NCT02174679 | 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) | no longer available | — | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT02826395 | C11 Sodium Acetate PET/CT Imaging of PCa | no longer available | — | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02531672 | Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography | no longer available | — | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT03702036 | Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma | no longer available | — | — | GlaxoSmithKlineINDUSTRY | 0 | Apr 13, 2020 | clinicaltrials |
| NCT02568943 | An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 6 | Apr 8, 2020 | clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
| NCT03460782 | An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas | no longer available | — | — | Center Trials & TreatmentOTHER | 8 | Nov 8, 2019 | clinicaltrials |
| NCT02297529 | Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma | no longer available | — | — | AmgenINDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03723057 | Expanded Access for AG-221 | no longer available | — | — | CelgeneINDUSTRY | 1 | Oct 24, 2019 | clinicaltrials |
| NCT02715843 | Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | no longer available | — | — | Molecular Templates, Inc.INDUSTRY | 1 | Oct 11, 2019 | clinicaltrials |
| NCT03503890 | Expanded Access to Rovalpituzumab Tesirine | no longer available | — | — | AbbVieINDUSTRY | 0 | Sep 10, 2019 | clinicaltrials |
| NCT03492489 | Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma | no longer available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Aug 1, 2019 | clinicaltrials |
| NCT03123952 | Expanded Access to ABT-414 | no longer available | — | — | AbbVieINDUSTRY | 0 | Jul 15, 2019 | clinicaltrials |
| NCT01538680 | Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy(CONSIGN) | no longer available | — | — | BayerINDUSTRY | 25 | May 29, 2019 | clinicaltrials |
| NCT03029481 | Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma | no longer available | — | — | Jonsson Comprehensive Cancer CenterOTHER | 0 | Mar 28, 2019 | clinicaltrials |
| NCT03529539 | Expanded Access for PSV Personalized Oncolytic Viruses(PSV) | no longer available | — | — | EpicentRx, Inc.INDUSTRY | 0 | Mar 6, 2019 | clinicaltrials |
| NCT03850704 | Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma | no longer available | — | — | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 22, 2019 | clinicaltrials |
| NCT02955446 | Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies | no longer available | — | — | University of Colorado, DenverOTHER | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03723096 | Expanded Access for CC-4047 | no longer available | — | — | CelgeneINDUSTRY | 1 | Dec 20, 2018 | clinicaltrials |
| NCT01834209 | A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | no longer available | — | — | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 7, 2018 | clinicaltrials |
| NCT02547675 | Rociletinib (CO-1686) USA Expanded Access Program | no longer available | — | — | Clovis Oncology, Inc.INDUSTRY | 1 | Sep 25, 2018 | clinicaltrials |
| NCT03409081 | Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | no longer available | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 13, 2018 | clinicaltrials |
| NCT02564224 | Study Comparing Pursestring Wound Closure vs Conventional Closure to Reverse Stoma of Colorectal Cancer Patients(PURSE) | no longer available | — | — | Zhejiang UniversityOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01777061 | Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan | no longer available | — | — | Wendell Yap, MDOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT03005262 | MLN8237 for a Subject With Adenocarcinoma of the Prostate | no longer available | — | — | The University of Texas Health Science Center at San AntonioOTHER | 0 | Apr 4, 2018 | clinicaltrials |
| NCT02784158 | An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer | no longer available | — | — | Ariad PharmaceuticalsINDUSTRY | 1 | Feb 6, 2018 | clinicaltrials |
| NCT02083484 | Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) | no longer available | — | — | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 26, 2018 | clinicaltrials |
| NCT03311542 | Expanded Access for Pembrolizumab (MK-3475) | no longer available | — | — | Center Trials & TreatmentOTHER | 4 | Jan 10, 2018 | clinicaltrials |
| NCT03068650 | Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut(CDX-110) | no longer available | — | — | Celldex TherapeuticsINDUSTRY | 0 | Oct 18, 2017 | clinicaltrials |
| NCT00210665 | A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment | no longer available | — | — | Janssen Research & Development, LLCINDUSTRY | 3 | Oct 10, 2017 | clinicaltrials |
| NCT03085186 | Treatment With Crizotinib Single Patient Expanded Access IND 134375 | no longer available | — | — | Jean M. Tersak, M.D.OTHER | 0 | Aug 29, 2017 | clinicaltrials |
| NCT02666209 | Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | no longer available | — | — | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2017 | clinicaltrials |
| NCT00701168 | Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer | no longer available | — | — | Leo W. Jenkins Cancer CenterOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT01980732 | 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors | no longer available | — | — | Andrei IagaruOTHER | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02416232 | Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma | no longer available | — | — | GlaxoSmithKlineINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT02473653 | Pilot Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With HER-2 Positive Metastatic Cancer | no longer available | — | — | University of PennsylvaniaOTHER | 1 | Aug 11, 2017 | clinicaltrials |
| NCT02824094 | Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC | no longer available | — | — | PfizerINDUSTRY | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01956253 | Single Subject Neratinib in Bladder Cancer (NRR) | no longer available | — | — | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 14, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Feb 18, 2021source: clinicaltrials